Observational studyAdvances in therapy2022

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study).

Bincy Abraham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.